Lai Shih-Wei, Lin Cheng-Li, Liao Kuan-Fu
College of Medicine, China Medical University, Taichung City, Taiwan.
Department of Family Medicine, China Medical University Hospital, Taichung City, Taiwan.
Clin Drug Investig. 2015 Oct;35(10):653-7. doi: 10.1007/s40261-015-0326-2.
No sufficient research has focused on the relationship between meloxicam use and acute pancreatitis. This study aimed to explore this issue in Taiwan.
This case-control study was conducted using the database of the Taiwan National Health Insurance Program. In all, there were 6780 cases aged 20-84 years who were newly diagnosed with acute pancreatitis during the period 1998-2011, and 21,393 control subjects without acute pancreatitis. Cases and controls were matched for sex, age and comorbidities. Odds ratios (ORs) and 95% confidence intervals (CIs) were measured to explore the associations between acute pancreatitis, meloxicam use and comorbidities, using a multivariable unconditional logistic regression model.
After controlling for potential confounding factors, the adjusted OR for acute pancreatitis was 1.76 (95% CI 1.30-2.40) for subjects with current use of meloxicam, in comparison with subjects who had never used meloxicam. The adjusted OR decreased to 1.29 (95% CI 0.82-2.03) for subjects with late use of meloxicam, but without statistical significance.
Current use of meloxicam is associated with increased odds of acute pancreatitis. Clinicians should consider the potential risk of acute pancreatitis when prescribing meloxicam.
关于使用美洛昔康与急性胰腺炎之间的关系，目前尚无足够的研究。本研究旨在探讨台湾地区的这一问题。
本病例对照研究使用了台湾全民健康保险计划的数据库。1998年至2011年期间，共有6780例年龄在20 - 84岁之间的新诊断为急性胰腺炎的病例，以及21393例无急性胰腺炎的对照对象。病例和对照按性别、年龄和合并症进行匹配。采用多变量无条件逻辑回归模型，测量比值比（OR）和95%置信区间（CI），以探讨急性胰腺炎、美洛昔康使用与合并症之间的关联。
在控制潜在混杂因素后，与从未使用美洛昔康的受试者相比，当前使用美洛昔康的受试者发生急性胰腺炎的调整后OR为1.76（95%CI 1.30 - 2.40）。美洛昔康延迟使用的受试者调整后OR降至1.29（95%CI 0.82 - 2.03），但无统计学意义。
当前使用美洛昔康与急性胰腺炎的发病几率增加有关。临床医生在开具美洛昔康处方时应考虑急性胰腺炎的潜在风险。
